On October 28, 2026, the U.S. Department of Health and Human Services (HHS) issued an interim policy that opens a path for licensed pharmacies to compound six peptides that had been effectively off limits. Here is what changed, what did not, and how Avono is getting ready.
Short on time? HHS will not take enforcement action against state-licensed pharmacies that compound BPC-157, epitalon, KPV, MOTS-c, Semax or TB-500 for individual patients with a prescription, as long as they meet strict quality and safety conditions. This is not FDA approval. Avono plans to be among the first providers to offer these peptides through licensed U.S. pharmacies. Join the early-access list.
What changed
Compounding pharmacies can only use certain bulk ingredients. For the last few years, many popular peptides were on the FDA’s list of substances that raised safety concerns, so licensed pharmacies did not compound them. The new HHS policy, signed by the HHS Secretary, says the government will not take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians that compound six peptides under 503A, the part of federal law that covers compounding for individual patients:
- BPC-157
- Epitalon
- KPV
- MOTS-c
- Semax
- TB-500
The conditions that come with it
- A prescription for an individual patient.
- Peptide ingredients from an FDA-registered maker, with a certificate of analysis showing what is in them.
- One active ingredient per product.
- Reporting of serious side effects to the FDA.
- A label that says it is a compounded drug.
- Extra proof for products taken by mouth that the body can actually absorb them.
What did not change
This is not FDA approval. HHS says the policy does not establish that these peptides are safe or effective, and most of the research on them comes from lab and animal studies, with few studies in people. The policy is interim: it applies while the FDA works through formal rulemaking, and HHS can revisit it if safety or quality problems appear. Products sold online as “research use only” are still not prescriptions and are not covered. Here is why that label matters.
Why Avono is ready to move early
We already prescribe peptides like sermorelin and PT-141 through licensed U.S. compounding pharmacies, with licensed clinicians reviewing every request. That means the basics the new policy is built on, prescriptions for individual patients, licensed U.S. pharmacies and clinician oversight, are already how we work.
We plan to be among the first providers to offer these compounded peptides, in the states where they are allowed, as soon as the pharmacies in our network can meet every condition of the policy. We will not cut corners to get there first.
Get early access to new peptides
Be first to know when new peptide treatments open at Avono. We will only email you about the launch.
You are on the list. We will email you when new peptides open.
We only use your email for launch news. No spam, and you can ask us to remove it anytime. Joining does not start a medical intake.
What you can do today
Join the list above and we will email you when new peptides open at Avono. In the meantime, you can explore the longevity and wellness treatments we offer now, including sermorelin, NAD+ and glutathione.
Prescription required. A licensed clinician decides whether treatment is right for you. Compounded peptides are not FDA approved, and the FDA does not review them for safety, effectiveness or quality. Availability depends on state rules and pharmacy readiness. This article is general information, not legal or medical advice.



